China-based WuXi PharmaTech has announced construction of a new, 145,000-square-foot cGMP facility in Philadelphia, Pennyslvania, for the manufacture of cell therapy products.
The new facility will be WuXi's third cell therapy manufacturing facility in Philadelphia, when it becomes operational by mid-2016. It will provide single-source contract development and cGMP manufacturing capabilities to support the rapidly growing cellular therapeutic industry's unique requirements.
The new facility expands on WuXi's existing 16,000-square-foot cGMP cell therapy manufacturing facility, as well as a 45,000-square-foot facility for the manufacturing of allogeneic and autologous cell-based therapeutics that is expected to be completed by mid-2015.
Read the Asian Scientist Magazine release